| 摘要 |
The present invention relates to a compound of the general formula (I): [Ar<SUB>1 </SUB>is aryl fused to the adjacent pyrazinone ring at the 5th and 6th positions, etc., X is CO, etc., Y is CH, etc., Z is CH, etc., V is CH, etc., W<SUB>n </SUB>is -(CH<SUB>2</SUB>)<SUB>n</SUB>- (n is zero to four), R<SUB>1 </SUB>is H or optionally substituted lower alkyl, etc., R<SUB>2 </SUB>is H, etc., R<SUB>3 </SUB>and R<SUB>4 </SUB>are the same or different and are each H, etc., R<SUB>5 </SUB>and R<SUB>6 </SUB>are the same or different and are each H, hydroxy, etc.] or a pharmaceutically acceptable salt or ester thereof; a pharmaceutical composition, an inhibitor of Cdk4 and/or Cdk6 or an anti-cancer agent, containing the same as an active ingredient; and a process for preparing them.
|
